Artur Nowak represented Evidence Prime at the World Evidence, Pricing & Access Congress 2026, held on 3–4 March at the RAI Congress Centre in Amsterdam. The meeting brought evidence generation, health technology assessment, pricing and reimbursement into the same discussion.
Connecting evidence reviews with access decisions
For Laser AI, this was an opportunity to consider how literature-review work fits into the wider process of assessing and communicating the value of a treatment. The programme connected evidence planning with real-world data, economic evaluation and the practical requirements of health technology assessment.
These connections matter because a review rarely ends with a list of included studies. Its outputs need to support the next stage of analysis, whether that involves comparing treatments, assessing the feasibility of a synthesis or preparing an evidence dossier. Clear methods and structured, traceable outputs help other members of the team understand what can be carried forward and where uncertainty remains.
AI across the evidence workflow
The AI and Digital Transformation track addressed practical uses of generative AI in HTA, alongside automation spanning literature reviews, feasibility assessment, indirect treatment comparisons and medical writing. These sessions placed AI within a sequence of evidence tasks, rather than treating a model response as the final deliverable.
For evidence teams, this raises a useful question: what needs to remain visible as work moves between those tasks? Source publications, study-selection decisions, extracted values and expert judgments each provide part of the answer. Evaluating an individual AI task is useful, but it also matters whether the complete process can be checked and reproduced.
Our attendance connected Laser AI’s evidence-synthesis perspective with this broader access community. The organizer’s 2026 post-event report provides further context on the congress and its programme.
